Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96BW5

UPID:
PTER_HUMAN

ALTERNATIVE NAMES:
Parathion hydrolase-related protein

ALTERNATIVE UPACC:
Q96BW5; B0YJ77; B3KTF5; D3DRU0; Q9BY46

BACKGROUND:
The Phosphotriesterase-related protein, with alternative names such as Parathion hydrolase-related protein, plays a crucial role in neutralizing organophosphate compounds. This enzyme's activity is vital for mitigating the effects of these toxic substances, which are prevalent in pesticides and nerve agents.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Phosphotriesterase-related protein offers a pathway to innovative therapeutic approaches. Its capacity to break down organophosphates positions it as a key target for creating treatments against poisoning from these compounds.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.